The convergence of biopharmaceuticals and consumer health technology reached an institutional milestone with Eli Lilly and Company’s disclosed interest in purchasing up to $100 million in common stock during the initial public offering of Oura Inc.. Lined up alongside an indicated cornerstone commitment of up to $300 million from Dragoneer Investment Group, the joint commitments represent approximately $400 million, or nearly 19% of the wearable maker’s public offering.

The primary client profile for Nelson Advisors comprises clinically originated or founder-led enterprises generating annual revenues between €5 Million and €50 Million, operating EBITDA from €1 Million to €10 Million, and maintaining head counts of 20 to 250 personnel. These organisations typically possess established, scalable technologies but lack in-house corporate development infrastructure to navigate institutional M&A processes, cross-border regulatory hurdles, and comp